Business · 12/04/2016Updated: 10/17/2026 · 1 min read
EMD Serono Withdraws FDA Approval for LUVERIS
Summary
EMD Serono has voluntarily withdrawn its new drug application for LUVERIS, a treatment for growth hormone deficiency, from the FDA, waiving its right to a hearing.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →